Azathioprine

connective tissue

Study Supports Use of Immunosuppressive Therapy for CTD-PAH

Researchers reported that existing evidence supports the use of immunosuppressive therapeutics in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH), especially in systemic lupus erythematosus-associated PAH (SLE-PAH), as published in the International Journal of Rheumatic Disease. PAH is primarily characterized by pulmonary vascular remodeling which increases pulmonary vascular resistance. The current thinking when it comes…

coronavirus vaccine

New Humoral Response Data Show COVID-19 Vaccine Is Useful in NMOSD

The humoral response becomes impaired after COVID-19 vaccination in patients with neuromyelitis optica spectrum disorder (NMOSD) treated with B-cell depleting therapies, a new study published in Multiple Sclerosis and Related Disorders found. However, seroconversion occurred in almost all patients treated with conventional synthetic disease-modifying immunosuppressants after COVID-19 infection or vaccination. The authors of the study…

T helper cells

Novel Insights Into Therapeutic Possibilities for NMOSD

Researchers highlighted the need to perform clinical trials for novel drugs to treat neuromyelitis optica spectrum disorders (NMOSD) in a timely manner and published their findings in CNS Neuroscience & Therapeutics. The review conducted by Shi et al referenced 107 publications regarding updates on NMOSD treatment. Although visible progress has been made to better understand…

graph

New Evidence Supports Rituximab as Initial Treatment for NMOSD

Researchers discovered that a reduced dose of rituximab as initial therapy reduces the risk of relapse compared to mycophenolate mofetil and is also better tolerated than azathioprine in patients with aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), as published in the European Journal of Neurology. Researchers assessed 353 patients with NMOSD with the occurrence of…

IPF

Sildenafil Should Be Considered for the Treatment of IPF, New Study Says

The idiopathic pulmonary fibrosis (IPF) drugs nintedanib, pirfenidone, and sildenafil likely reduce mortality in patients with IPF, according to a systematic review of the literature and network meta-analysis of 22 approved or studied treatments for IPF. The investigational drug pamrevlumab may also reduce mortality. The prognosis of IPF remains poor. The effectiveness of available drugs…

Researchers Highlight Pediatric NMOSD Cases to Help Improve Prognosis

Most pediatric cases of neuromyelitis optica spectrum disorder (NMOSD) differed from adult cases due to antibody destruction of myelin oligodendrocyte glycoproteins (MOGs) as opposed to anti-aquaporin-4 (AQP4) autoantibodies, according to results from a study published in Multiple Sclerosis and Related Disorders. Both AQP4 and MOG antibodies necessitated the constant implementation of immunosuppressive treatments to improve…

Rituximab Could Be First-Line Treatment for NMOSD

Researchers discovered that rituximab demonstrated sufficient efficiency and safety for the treatment of neuromyelitis optica spectrum disorder (NMOSD), as published in Therapeutic Advances in Neurological Disorders. This makes it a suitable candidate for the first-line treatment of NMOSD. Rituximab was accepted to treat NMOSD in 2005 because it therapeutically targets antibody-producing B cells and the…

Next post in NMOSD News Briefs